ClinicalTrials.gg
CompletedNCT02284516OPUS-3Updated Jun 11, 2021Results posted

A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)

A Phase 3 interventional study of Lifitegrast and Placebo in Dry Eye Disease, sponsored by Shire. Completed at 41 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-11.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
711
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing lifitegrast in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. lifitegrast · Dry Eye Syndromes.

Enrollment
2nd of 22
711 · median 38
Started
2014
the only one that year
Phase 3
5 of 22
none open now
Registered
5th of 22
by date
Lead sponsor
5 of 22
Shire

Among the 22 studies testing lifitegrast in Dry Eye Syndromes, this one is the 2nd largest by enrollment, is the only one that started in 2014, is one of 5 in phase 3, and was the 5th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

2 of the 22 studies testing lifitegrast in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About lifitegrast

lifitegrast: first FDA approval 2016 (XIIDRA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing lifitegrast in Dry Eye Syndromes, or all of them as a file.
02

Study summary

Evaluate the efficacy and safety of Lifitegrast in subjects with dry eye disease and a recent history of artificial tear use.

03

Conditions studied

  • Dry Eye Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient-reported history of Dry Eye Disease in both eyes.
  • Use of over the counter artificial tears within the past 30 days.
  • A negative urine pregnancy test for females and willingness to use adequate throughout the study.
  • Able and willing to comply with all study procedures.

Exclusion criteria

Exclusion Criteria:

  • Presence of an ocular condition that could affect the study parameters such as active ocular infections, ocular inflammation, glaucoma, or diabetic retinopathy;.
  • Unwilling to stop wearing contact lenses during the study.
  • LASIK or other ocular surgical procedures within 12 months prior to or during the study.
  • Use of prohibited medications
  • Significant medical conditions that could affect the study parameters.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
711 participants (actual)

Study arms

  • Experimental
    Lifitegrast

    Lifitegrast Ophthalmic Solution 5%, BID for 84 days

    Drug: Lifitegrast

  • Placebo comparator
    Placebo

    Placebo to match active treatment, BID for 84 days

    Drug: Placebo

Interventions

  • Lifitegrast Ophthalmic Solution 5%, BID for 84 days

  • DrugPlacebo

    Placebo to match active treatment, BID for 84 days

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Patient-Reported Eye Dryness Score to Day 84

    Eye dryness score was scored on a Visual Analogue Scale (VAS) ranges from 0-100 (0=no discomfort; 100=maximal discomfort).

    Time frame: Baseline to Day 84

Secondary outcomes

  1. Change From Baseline in Patient-Reported Eye Dryness Score to Day 14 and Day 42

    Eye dryness score was scored on a Visual Analogue Scale (VAS) ranges from 0-100 (0=no discomfort; 100=maximal discomfort).

    Time frame: Baseline to Day 14 and Day 42

07

Results

Posted Mar 15, 2017

Participant flow

Participant flow — Overall Study
MilestonePlaceboLifitegrast
Started356355
Safety population354357
Completed318319
Not completed3836

Outcome measures

PrimaryChange From Baseline in Patient-Reported Eye Dryness Score to Day 84

Eye dryness score was scored on a Visual Analogue Scale (VAS) ranges from 0-100 (0=no discomfort; 100=maximal discomfort).

Time frame:
Baseline to Day 84
Reported as:
Mean · units on a scale
Change From Baseline in Patient-Reported Eye Dryness Score to Day 84
units on a scalePlaceboLifitegrast
Baseline (n=356, 355)69.0 ± 17.0868.3 ± 16.88
Change from Baseline to Day 84 (n=353, 353)-30.7 ± 28.01-37.9 ± 28.85
Statistical analysis
  • Placebo vs Lifitegrast · ANOVA · p = =0.0007 (The primary analysis was performed using a stratified 2-sample t-test (that is, analysis of variance \[ANOVA\]).) · Treatment effect: 7.16 · 95% CI 3.04 to 11.28
SecondaryChange From Baseline in Patient-Reported Eye Dryness Score to Day 14 and Day 42

Eye dryness score was scored on a Visual Analogue Scale (VAS) ranges from 0-100 (0=no discomfort; 100=maximal discomfort).

Time frame:
Baseline to Day 14 and Day 42
Reported as:
Mean · units on a scale
Change From Baseline in Patient-Reported Eye Dryness Score to Day 14 and Day 42
units on a scalePlaceboLifitegrast
Baseline (n=356, 355)69.0 ± 17.0868.3 ± 16.88
Change from Baseline to Day 14 (n=353, 352)-15.0 ± 22.40-22.9 ± 25.44
Change from Baseline to Day 42 (n=353, 353)-23.9 ± 25.99-33.2 ± 27.42
Statistical analysis
  • Placebo vs Lifitegrast · ANOVA · p = <0.0001 (The primary analysis was performed using a stratified 2-sample t-test (that is, analysis of variance \[ANOVA\]).) · Treatment effect: 7.85 · 95% CI 4.33 to 11.37
  • Placebo vs Lifitegrast · ANOVA · p = <0.0001 (The primary analysis was performed using a stratified 2-sample t-test (that is, analysis of variance \[ANOVA\]).) · Treatment effect: 9.32 · 95% CI 5.44 to 13.20

Adverse events

Collected over From start of the study drug administration upto Day 91 or Early termination (ET). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—4/354 (1.1%)30/354 (8.5%)
Lifitegrast—4/357 (1.1%)107/357 (30%)
Most frequent serious events
Most frequent serious events
EventPlaceboLifitegrast
Periprosthetic fractureInjury, poisoning and procedural complications1/3540/357
Lower limb fractureMusculoskeletal and connective tissue disorders1/3540/357
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3540/357
Accelerated hypertensionVascular disorders1/3540/357
PneumoniaInfections and infestations0/3541/357
Cerebrovascular accidentNervous system disorders0/3541/357
Transient ischaemic attackNervous system disorders0/3541/357
Lung neoplasm malignantRespiratory, thoracic and mediastinal disorders0/3541/357
Most frequent other events
Most frequent other events
EventPlaceboLifitegrast
Instillation site irritationGeneral disorders11/35465/357
DysgeusiaNervous system disorders1/35446/357
Instillation site reactionGeneral disorders19/35445/357

Baseline characteristics

Randomized population included all participants screened for whom a randomization number was assigned.

Age, Continuous
Age, Continuous(years)PlaceboLifitegrastTotal
Mean58.6 ± 14.8458.8 ± 14.1058.7 ± 14.47
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLifitegrastTotal
Female269268537
Male8787174
08

Study locations

41 sites
  • University of Alabama at Birmingham, UAB School of Optometry
    Birmingham, Alabama 35294, United States
  • Arizona Eye Center
    Chandler, Arizona 85225, United States
  • Sall Research Medical Center
    Artesia, California 90701, United States
  • United Medical Research Institute
    Inglewood, California 90301, United States
  • North Valley Eye Medical Group, Inc
    Mission Hills, California 91345, United States
  • Montebello Medical Eye Center, Inc.
    Montebello, California 90640, United States
  • Eye Research Foundation
    Newport Beach, California 92663, United States
  • Arch Health Partners
    Poway, California 92064, United States
  • Martel Eye Medical Group
    Rancho Cordova, California 95670, United States
  • Shasta Eye Medical Group, Inc.
    Redding, California 96001, United States
  • West Coast Eye Care Associates
    San Diego, California 92115, United States
  • Chicago Cornea Consultants, Ltd.
    Hoffman Estates, Illinois 60169, United States
  • Jackson Eye, SC
    Lake Villa, Illinois 60046, United States
  • Price Vision Group
    Indianapolis, Indiana 46260, United States
  • John-Kenyon American Eye Institute
    New Albany, Indiana 47150, United States
  • Koffler Vision Group
    Lexington, Kentucky 40509, United States
  • The Eye Care Institute
    Louisville, Kentucky 40206, United States
  • Holpro Vision, Ltd.
    Union, Kentucky 41091, United States
  • Clinical Eye Research of Boston
    Winchester, Massachusetts 01890, United States
  • Lifelong Vision Foundation
    Chesterfield, Missouri 63017, United States
  • Tauber Eye Center
    Kansas City, Missouri 64111, United States
  • Tekwani Vision Center
    Saint Louis, Missouri 63128, United States
  • Ophthalmology Consultants, Ltd.
    Saint Louis, Missouri 63131, United States
  • Comprehensive Eye Care, Ltd.
    Washington, Missouri 63090, United States
  • Wellish Vision Institute
    Las Vegas, Nevada 89119, United States
  • Abrams Eye Institute
    Las Vegas, Nevada 89148, United States
  • Clinical Vision Research Center at SUNY
    New York, New York 10036, United States
  • Ophthalmic Consultants Of Long Island
    Rockville Centre, New York 11570, United States
  • South Shore Eye Care, LLP
    Wantagh, New York 11793, United States
  • Abrams Eye Center
    Cleveland, Ohio 44115, United States
  • Scott & Christie and Associates, PC
    Cranberry Township, Pennsylvania 16066, United States
  • Matossian Eye Associates
    Doylestown, Pennsylvania 18902, United States
  • Toyos Clinic
    Nashville, Tennessee 37203, United States
  • The Cataract & Glaucoma Center
    El Paso, Texas 79902, United States
  • Advanced Laser Vision and Surgical Institute
    Houston, Texas 77034, United States
  • Whitsett Vision Group
    Houston, Texas 77056, United States
  • University of Houston College of Optometry
    Houston, Texas 77204, United States
  • The Eye Clinic of Texas (Houston Eye Associates)
    League City, Texas 77573, United States
  • Eye Clinics of South Texas, P.A.
    San Antonio, Texas 78209, United States
  • R and R Eye Research, LLC.
    San Antonio, Texas 78229, United States
  • See Clearly Vision
    McLean, Virginia 22012, United States
09

References and documents

Publications

  • Holland EJ, Jackson MA, Donnenfeld E, Piccolo R, Cohen A, Barabino S, Rolando M, Figueiredo FC. Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials. JAMA Ophthalmol. 2021 Nov 1;139(11):1200-1208. doi: 10.1001/jamaophthalmol.2021.3943. PubMed 34617974 ↗
  • Holland EJ, Luchs J, Karpecki PM, Nichols KK, Jackson MA, Sall K, Tauber J, Roy M, Raychaudhuri A, Shojaei A. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3). Ophthalmology. 2017 Jan;124(1):53-60. doi: 10.1016/j.ophtha.2016.09.025. Epub 2016 Oct 27. PubMed 28079022 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Oct 2015, 10 months.

Results were first posted in Mar 2017, 1 year 5 months after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 10 months is above that.

Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2014
First posted
Nov 6, 2014
StartActual
Nov 6, 2014
Primary completionActual
Oct 5, 2015
CompletionActual
Oct 5, 2015
Results first posted
Mar 15, 2017
Last update
Jun 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02284516
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Nov 6, 2014
Start date
Nov 6, 2014
Primary completion
Oct 5, 2015
Completion
Oct 5, 2015
Results posted
Mar 15, 2017
Last update
Jun 11, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lifitegrast

Start the discussion